Drug intelligence / Profile preview

simvastatin + dabigatran etexilate

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

This is not an intentional combination therapy but rather a drug interaction of clinical significance. Simvastatin is a cholesterol-lowering medication (statin) administered as an inactive lactone prodrug. Dabigatran etexilate is an oral direct thrombin inhibitor anticoagulant used to prevent stroke in patients with atrial fibrillation. When used together, simvastatin can inhibit P-glycoprotein, potentially increasing dabigatran absorption and blood levels, which may lead to an increased risk of major hemorrhage.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CES1 (Liver carboxylesterase 1)F2 (Thrombin)ABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on simvastatin + dabigatran etexilate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simvastatin + dabigatran etexilate.

Explore the full profile